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Available online 15 May 2015AbstractBackground: Recent advances in gastric cancer chemotherapy have made macroscopic complete resection possible in some patients with
stage IV disease.
Methods: We retrospectively investigated the efficacy of multimodal therapy with combined docetaxel, cisplatin, and S-1 (DCS) and con-
version gastrectomy in 57 patients with stage IV gastric cancer.
Results: Of the 57 patients, 15 patients were categorized into potentially resectable case, which is defined as patients with single incurable
factor including the upper abdominal para-aortic lymph node metastasis (16a2b1 PAN metastasis) or fewer than three peripheral liver me-
tastases. The other 42 were categorized as initially unresectable. All of patients underwent DCS therapy, and then 34 patients underwent
conversion gastrectomy. The 3-year overall survival (OS) rate among the patients who underwent conversion gastrectomy was 50.1% with
MST of 29.9 months. They had significantly longer OS than patients who underwent DCS therapy alone (p < 0.01). Univariate analysis
among the patents with conversion gastrectomy identified 16a2b1PAN metastasis, peritoneal metastasis, potential resectable case, R0 resec-
tion as significant prognostic factors. A 3-year OS in potential resectable cases was 92.9%. Multivariate analysis identified potential resect-
ability as the only independent prognostic factor contributing to OS (HR 0.133, 95%CI 0.024-0. 744, p ¼ 0.021). In contrast, clinical
response was selected as the only independent prognostic factor in the subgroup of initially unresectable cases (HR 0.354, 95%CI
0.151-0.783, p ¼ 0.021).
Conclusion: Patients with potentially resectable disease had a remarkably good prognosis among stage IV gastric cancer patients, and might
be ideal candidates for conversion gastrectomy following DCS therapy.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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Chemotherapy is the main treatment for stage IV gastric
cancer associated with distant metastasis. Although there is
currently no established global standard chemotherapy for
stage IV gastric cancer, combination therapy with a fluoro-
pyrimidine and platinum is commonly used worldwide.1hor. Tel.: þ81 76 265 2362; fax: þ81 76 234 426.
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).The orally administered, 5-FU analog S-1 has been used
as a good alternative to continuous infusion of 5-FU in un-
resectable gastric cancer in Japan, according to the JCOG
9912 Trial.2 A multicenter phase III trial of unresectable
gastric cancer (SPIRITS trial) comparing S-1 alone with
S-1 plus cisplatin yielded a significantly higher response
rate and improved overall survival (OS) in patients
receiving the combined treatment.3 S-1 plus cisplatin is
thus the current standard treatment regimen for advanced
gastric cancer in Japan. Moreover, several Phase I andess article under the CC BY-NC-ND license (http://creativecommons.org/
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tion of docetaxel, cisplatin and S-1 (DCS) in patients with
highly advanced gastric cancer, and these trials demon-
strated high response rate: 76.9e87.1%.4e6 DCS therapy
is expected to become the standard regimen for advanced
gastric cancer in Japan.
These advances in gastric cancer chemotherapy have
raised new clinical issues regarding the treatment of stage
IV gastric cancer. The response rate of newly-developed
chemotherapeutic regimens has improved dramatically, al-
lowing the down-staging of many tumors and the further
management of gastric cancer patients whose distant metas-
tases have clinically disappeared or which are well
controlled by chemotherapy. Surgical intervention in such
patients may result in long-term survival after the excision
of macroscopically remaining lesions. This type of surgery,
referred to as conversion gastrectomy, aims to be curative
rather than just palliative, on the basis of the response to
chemotherapy. However, the clinical value of such multi-
modal therapy involving chemotherapy and conversion gas-
trectomy for stage IV gastric cancer remains controversial,
especially in initially unresectable patients, because of the
presence of widespread advanced systemic disease.
In this study, we retrospectively investigated the feasi-
bility and efficacy of multimodal DCS therapy and conver-
sion gastrectomy for stage IV gastric cancer patients, with
particular focus on the potential to select patients who
might benefit from surgical resection.
Materials and methodsPatientsWe retrospectively identified patients with a clinical
diagnosis of stage IV gastric adenocarcinoma who under-
went DCS therapy as primary chemotherapy at our institute
between April 2006 and March 2012. The inclusion criteria
were as follows: (1) newly diagnosed with gastric adeno-
carcinoma; (2) clinically diagnosed with unresectable
and/or metastatic lesions; (3) underwent at least one cycle
of DCS therapy as primary chemotherapy; (4) Eastern
Cooperative Oncology Group performance status 0e1;
and (5) no prior chemotherapy, radiotherapy, or major sur-
gical procedure; (6) provision of signed written informed
consent.
A total of 57 patients were included in the current study.
The patients enrolled in this study had one or more of the
following factors indicating incurable cancer: liver metas-
tasis, peritoneal metastasis, and/or distant lymph node
metastasis clearly enlarged (S1.0 cm) on CT scans with
2.5 mm slice thickness.
We also stratified patients into two categories depending
on their cancer status at the time of initial diagnosis: (1)
potentially resectable cases, who had single incurable fac-
tor including para-aortic lymph node (PAN) metastasis be-
tween the upper margin of the celiac artery and the lowerborder of the inferior mesenteric artery which are defined
as lymph node station No. 16a2 and b1 according to
JCGC 3rd English edition (16a2b1PAN),7 or fewer than
three peripheral liver metastasis lesions; and (2) initially
unresectable cases who had other incurable factor or
more than one incurable factor. In the current study, para-
aortic lymph node metastasis around the upper side of the
celiac artery (16a1) or lower side of inferior mesenteric ar-
tery (16b2) was defined as distant lymph node metastasis.
This study was approved by the institutional review
board of Kanazawa University Graduate School of Medical
Sciences. Written informed consent was obtained from all
patients.Treatment regimenDCS therapy consisted of docetaxel 35 mg/m2 and
cisplatin 35 mg/m2 as an intravenous infusion on Days 1
and 15, and S-1 administered at a dose of 80 mg/m2/day
divided into two split daily doses for 14 days, followed
by 14 days of rest, as described previously.4The clinical
response for measurable metastatic tumors was evaluated
based on the guidelines of the Response Evaluation Criteria
in Solid Tumors (RECIST) guidelines version 1.0. The clin-
ical response for primary lesions was defined according to
JCGC 3rd edition.7Clinical assessment of surgery and histological
evaluation of surgical specimenIn patients in whom distant lesions were controlled or
disappeared during the course of chemotherapy, the indica-
tion for surgery was determined based on the response to
chemotherapy. In the present study, conversion gastrec-
tomy was defined as surgery with curative intent aimed
at leaving no macroscopic residual tumor. Complete
regression of immeasurable lesions such as peritoneal
metastasis was confirmed by laparoscopic examination
before gastrectomy.
To ensure the feasibility of conversion surgery, this study
included all surgeries that eventually resulted in incomplete
resection. Surgical complications were assessed according
to the ClavieneDindo classification. All resected speci-
mens were examined by the same pathologist to assess
the extent of residual disease, disease stage, and effect of
chemotherapy according to the criteria of JCGC 3rd edi-
tion.7 Tumors were graded as 0e3 based on the degree of
necrosis or disappearance of the tumor in relation to the
estimated total amount of the lesion.Statistical analysisOS was calculated from the date of chemotherapy initi-
ation to death from any cause or the latest follow-up. The
median OS was estimated using the KaplaneMeier method
and differences in survival were evaluated using the log-
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vival were analyzed by multivariate analyses using the
Cox proportional hazards method. All statistical evalua-
tions were performed using the SPSS 11.5J software pack-
age (SPSS Japan Inc., Tokyo, Japan). A p value <0.05
(two-tailed) was considered statistically significant.ResultsPatient characteristics and clinical outcomes of DCS
therapyTable 1 shows the clinicopathological characteristics and
clnical outcomes of DCS thepray in all patients enrolled in
this study. Incurable factors included 16a2b1 PAN metas-
tasis in 23 patients, liver metastasis in 18, distant lymph
node metastasis in 17, peritoneal metastasis in 15, and
bone metastasis in 2. Some of these numbers of patients ac-
cording to incurable factors included overlapped data.
Among those with liver metastases, 13 patients had multi-
ple metastatic lesions and five had fewer than three periph-
eral lesions. Fifteen patients were categorized as potentially
resectable according to metastatic status (10 with 16a2b1Table 1
Patient characteristic and clinical outcomes of DCS therapy.
Characteristic Number of patients
Sex (male/female) 38/19
Age (years), range (median) 30e78 (65)
Performance status 0/1/2/3/4 40/17/0/0/0
Tumor location U/M/L/Whole 15/13/18/11
Depth of tumor invasion
T1/T2/T3/T4a/T4b
0/11/20/20/6
Histological type intestinal/diffuse 29/28
Borrmann macroscopic type 1/2/3/4 0/19/28/10
Incurable factor
16a2b1Para-aortic lymph node metastasis 23
Distant lymph node metastasis 17
Peritoneal metastasis 15
Liver metastasis 18
Other hematogenous metastasis 2
Number of incurable factors, 1/2/3/4 31/17/2/7
Potentially resectable/Initially
unresectable cases
15 (16a2b1PAN:
10 liver: 5)/42
Number of treatment cycles,
range (median)
1e7 (2)
Clinical response of DCS therapy
CR/PR/SD/PD/NE
0/42/8/3/4
% of Grade 3 or 4 toxicity
Leukopenia 17.5
Neutropenia 31.6
Thrombocytopenia 1.8
Anemia 7.0
Anorexia 7.0
GI bleeding 5.3
Hyponatremia 3.5
Febrile neutropenia 7.0
Conversion gastrectomy þ/ 34/23PAN metastasis, 5 with liver metastasis), and the remaining
42 were categorized as initially unresectable.
All patients enrolled in this study underwent primary
chemotherapy with DCS. The median number of courses
of DCS was two (range 1e7). The clinical overall re-
sponses were partial response in 42 (73.7%), stable disease
in eight (14.0%), progressive disease in three (5.3%), and
not evaluable in four patients (7.0%). No patient had a com-
plete response during DCS therapy. The overall response
rate was 73.7% and the disease-control rate was 87.7%.
The treatment-related toxicities of grade 3 or above
included neutropenia (31.6%), leukopenia (17.5%), and
febrile neutropenia (7.0%). Three patients experienced
grade 3 gastrointestinal bleeding from the primary tumor.
There were no patients who could not undergo conversion
gastrectomy due to DCS-related toxicities and there were
no treatment-related deaths in this study.
Thirty four patients (59.6%), including all the poten-
tially resectable cases, underwent conversion gastrectomy
following DCS therapy, while the other 23 (40.4%) under-
went chemotherapy alone.Surgical outcomesA total of 34 patients underwent conversion surgery with
curative intent after DCS therapy. The surgical procedures
and outcomes are shown in Table 2. The median duration
from the initiation of DCS therapy to surgery was 85
days (range 43e414 days). D2 lymphadenectomy plus
PAN dissection was performed in 17 patients. Complete
resection with no residual tumor (R0) was achieved in 27
of 34 patients, microscopic residual tumor status (R1) in
one (positive for peritoneal washing cytology), and macro-
scopic residual tumor (R2) in six (peritoneal metastasis in
four, lymph node metastasis in two). Eleven patients
(32.4%) developed postoperative complications. Patholog-
ical response (grade 1b) in the primary lesion was
observed in 64.7% of patients, with grade 3 in two patients.Postoperative chemotherapyIn this study, 32 of 34 patients were given postoperative
chemotherapy after conversion gastrectomy. S-1-combined
regimens were selected in 22 patients; DCS therapy in 4, S-
1 plus paclitaxel in one, and S-1 alone in 17. Weekly pacli-
taxel treatment was administered to four patients, irinote-
can to five patients, and capecitabine plus cisplatin to
one. The median number of courses of postoperative S-1-
combined chemotherapy was five (range 1e16 courses).Survival and prognostic factorsAmong all 57 patients, the 1-, 2-, and 3-year OS rates
were 70.6%, 49.6%, and 41.3%, respectively with an
MST of 20.9 months (Fig. 1A). The 3-year OS in the 34 pa-
tients who underwent conversion gastrectomy was 50.1%,
Table 2
Surgical outcomes in 34 patients who underwent conversion gastrectomy.
Variable Number of patients (%)
Total number of patients who underwent
conversion gastrectomy
34 (100%)
Surgical procedures
Total gastrectomy 22 (64.7%)
Distal gastrectomy 9 (26.5%)
Proximal gastrectomy 3 (8.8%)
Surgical time (min), range (median) 170e690 min (338)
Intraoperative blood loss (ml),
range (median)
70e2810 ml (750)
D2 lymphadenectomy plus
PAN dissection
17 (50.0%)
Resection of the other organs
Spleen 7 (20.1%)
Liver 5 (14.7%)
Colon 2 (5.9%)
Lower esophagus with
median phrenotomy
3 (8.8%)
Distal pancreas 2 (5.9%)
Peritoneal lavage cytology þ/ 1 (3.2%)/30 (96.8%)
Residual tumor status
R0 27 (79.4%)
R1 1 (2.9%)
R2 6 (17.7%)
Pathological response
Grade 0 3
Grade 1a 9
Grade 1b 9
Grade 2 11
Grade 3 2
Morbidity ClavieneDindo classification
Pancreatic fistulae 3 (8.8%) grade II/IIIa:1/2
Lymphatic fistulae 5 (14.7%) grade I/II: 1/4
Anastomotic leakage 1 (2.9%) grade IIIa
Intra-abdominal abscess 1 (2.9%) grade IIIa
Post operative ileus 1 (2.9%) grade II
Mortality 0 (0%)
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23 patients with chemotherapy alone was 0% with MST of
9.6 months (Fig. 1B). Among the patients who underwent
conversion gastrectomy, the 15 potentially resectable cases
exhibited the 3-year OS of 92.9% and the OS rate of poten-
tially resectable cases was significantly higher than that of
initially unresctable cases ( p < 0.01) as shown in Fig. 1C.
All potentially resectable cases underwent surgical resec-
tion after DCS therapy, whereas 19 of 42 patients under-
went surgical resection in initially unresectable cases.
MSTs and 3-year OS rates according to various prog-
nostic factors in 34 patients who underwent conversion gas-
trectomy are shown in Table 3. Among these patients,
univariate analysis identified 16a2b1 PAN metastasis, peri-
toneal metastasis, potential resectability, and residual tumor
status as significant prognostic factors. Multivariate anal-
ysis revealed potential resectability as the only independent
prognostic factor contributing to OS (hazard ratio 0.133,
95%CI 0.024-0.744, p ¼ 0.021).
Subsequently, various prognostic factors in 42 patients
who were categorized as initially unresectable wereinvestigated as shown in Table 4. Univariate analysis iden-
tified clinical response and conversion surgery as the signif-
icant prognostic factor ( p ¼ 0.023, 0.048, respectively).
Subsequent multivariate analysis of prognostic factors
with p < 0.1 in univariate analysis identified clinical
response to chemotherapy as the only independent prog-
nostic factor contributing to OS (hazard ratio 0.354, 95%
CI 0.151e0.783, p ¼ 0.036) in the subgroup of initially un-
resectable cases.
Discussion
Advances in gastric cancer chemotherapy including the
introduction of new anticancer agents and the development
of multi-agent regimens, have made macroscopic complete
resection possible in some patients with stage IV gastric
cancer. This type of surgery is referred to as conversion
gastrectomy with curative intent, and differs from palliative
gastrectomy. Surgical resection for residual tumors has
been reported as salvage gastrectomy, adjuvant gastrec-
tomy, or secondary surgery.8e14 They reported clinical ben-
efits of gastrectomy following various combination
chemotherapies and presented median survival that ranged
from 22 to 53 months. However, the chemotherapeutic reg-
imens administered in most of these studies, such as S-1
plus paclitaxel or S-1 plus docetaxel were not the current
standard treatments for stage IV gastric cancer, while
some reports included more than one regimen in the same
study. These clinical issues make it difficult to draw firm
conclusions about the optimum role of chemotherapy in
the setting of conversion gastrectomy.
In the current study, we investigated stage IV gastric
cancer patients who underwent DCS therapy, regardless
of conversion gastrectomy. This triple combined therapy
showed high response rate in several phase I and II trials:
76.9e87.1%4e6 and is expected to become the standard
regimen for advanced gastric cancer in Japan. Our data
show that the rate of conversion gastrectomy following
DCS therapy was 59.6% and patients undergoing conver-
sion gastrectomy have longer survival compared with pa-
tients receiving chemotherapy alone. The resection rate of
our study is high compared with that of the previous studies
with double combined therapy. In the SPIRITS trial, 7 of
148 patients (4.7%) underwent surgical resection following
S-1 plus cisplatin.3 Fukuchi et al. reported 40 of 151 pa-
tients (26.5%) with stage IV gastric cancer underwent con-
verstion surgery following S-1 plus cisplatin or paclitaxel.14
Our data also reveal that the 3-year OS rate of potentially
resectable cases was 92.9%, compared with a 3-year OS
rate in unresectable cases of only 35.1% (p < 0.01). Multi-
variate analysis indentified potentially resectable disease is
the only significant and independent factor associated with
OS in patients undergoing conversion gastrectomy. These
results indicate the potentially resectable cases can be ex-
pected long-term survival by conversion gastrectomy
following DCS therapy and be ideal candidates for this
Figure 1. (A) Overall survival rates in all study patients. (B) Overall survival rates in patients with conversion surgery and those with chemotherapy alone. (C)
The differences in overall survival rates between potentially resectable and initially unresectable cases who underwent conversion gastrectomy.
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Table 3
Survival and various prognostic factors in 34 patients who underwent conversion gastrectomy.
Variable Univariate analysis Multivariate analysis
Number of patients MST (months) 3-yr OS (%) p value HR 95% CI p value
Sex, male/female 23/11 59.9/27.3 61.7/37.9 0.327 e e e
Age (<70/S70 years) 23/11 47.7/18.8 53.7/48.7 0.909 e e e
ECOG performance status (0/1) 26/8 24.7/20.0 56.2/37.5 0.456 e e e
Bormann macroscopic type (2 or 3/4) 10/24 18.9/47.7 48.2/54.0 0.994 e e e
Differentiation (intestinal/diffuse) 24/10 47.7/18.7 58.2/35.6 0.386 e e e
Number of incurable factors (1/S2) 24/10 59.9/20.0 64.6/25.9 0.067 e e e
16a2b1 PAN metastasis (þ/) 18/16 e/18.9 72.9/15.2 0.047 1.229 0.278e5.426 0.786
Liver metastasis (þ/) 11/23 18.9/33.4 40.4/57.9 0.367
peritoneal metastasis (þ/) 4/30 6.54/52.1 0.0/27.9 <0.01 3.173 0.613e16.42 0.169
Potentially resectable/Initially unresectable 15/19 e/17.1 90.1/26.3 <0.01 0.133 0.024e0.744 0.021
Clinical response (PR/SD, PD or NE) 29/5 27.0/e 49.8/66.7 0.455 e e e
Residual tumor status R0/R1 or 2 27/7 e/15.6 63.5/16.0 <0.01 0.494 0.108e2.252 0.362
Pathological response grade S1b/0 or 1a 21/13 51.8/17.1 59.7/47.0 0.316 e e e
Table 4
Survival and various prognostic factors in initially unresectable cases.
Univariate analysis Multivariate analysis
Variable Number of patients MST (months) 3-yr OS (%) p value HR 95% CI p value
Sex (male/female) 27/15 13.1/15.9 38.2/0.0 0.838 e e e
Age (<70/S70 years) 35/7 17.0/15.6 22.6/15.1 0.264 e e e
ECOG performance status (0/1) 27/15 16.0/9.6 22.2/23.8 0.377 e e e
Differentiation (intestinal/diffuse) 17/25 19.9/12.7 35.7/0 0.085 2.167 0.709e4.165 0.231
Number of incurable factors (1/2) 16/26 11.7/19.9 26.2/24.5 0.167 e e e
clinical response (PR/SD,PD or NE) 31/11 17.05/6.6 27.2/0.0 0.023 0.354 0.151e0.783 0.036
Conversion surgery (þ/) 19/23 19.6/9.6 24.7/0.0 0.048 1.876 0.207e1.219 0.128
Peritoneal metastasis (þ/) 15/27 9.6/16.3 9.3/27.6 0.155 e e e
16a2b1 PAN metastasis (þ/) 13/29 16.0/13.1 37.0/10.6 0.171 e e e
Liver metastasis (þ/) 13/29 15.6/16.0 27.5/20.2 0.994 e e e
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cancer.
PAN metastasis is generally recognized as a non-
curative factor because the 5-year overall survival rate of
patients with PAN metastasis can be as high as 20% even
after radical dissection.15 Therefore, additional therapies
besides curative resection have been developed to improve
treatment outcome. Recently, several studies presented the
efficacy of preoperative chemotherapy and curative resec-
tion in patients with pathologically positive PAN.4,16 The
results of the current study are consistent with recent find-
ings regarding multimodality therapy in patients with PAN
metastasis arising from gastric cancer.
Liver metastasis is present in 4e14% of gastric cancer
patients at diagnosis.17,18 The role of hepatectomy in
gastric cancer is controversial. Only a few patients with
limited liver metastasis are thought to gain a survival
benefit from hepatectomy, because it usually occurs in the
setting of multiple lesions in gastric cancer. Takemura
et al. reported 1-, 3-, and 5-year OS rates after macroscop-
ically complete liver resection (n ¼ 64) of 84%, 50%, and
37%, respectively, in patients with fewer than three meta-
static lesions.19 However, previous studies showed thatrecurrence rate after hepatectomy for liver metastasis
from gastric cancer was 63.6e91.0%.20e25 This result indi-
cates the importance of controlling the micrometastasis by
additional systemic therapy. Chen et al. reported on the use
of preoperative chemotherapy for liver metastases as an
adjunct to surgery with MST of 22.3 months.26 In this
study, we defined potentially resectable liver metastases
as those involving fewer than three peripheral lesions,
because synchronous major hepatectomy with gastrectomy
after DCS therapy may increase morbidity and mortality as
a result of operative stress. We found 1-, 2-, and 3-year OS
rates of 100%, 80%, and 80%, with no operative mortality.
In contrast, it remains unclear whether conversion gas-
trectomy improves the prognosis in initially unresectable
cases; although univariate analysis indicated that initially
unresectable patients who underwent conversion gastrec-
tomy had significantly longer survival than those who
received chemotherapy alone ( p ¼ 0.048), multivariate
analysis showed that clinical response to chemotherapy
was the most important factor affecting prognosis in
initially unresectable cases ( p ¼ 0.021). Our results thus
suggest that conversion gastrectomy in initially unresect-
able patients should be considered with caution, even if
1360 J. Kinoshita et al. / EJSO 41 (2015) 1354e1360distant metastases have disappeared or are controlled by
chemotherapy. This represents an important issue in terms
of deciding which patients are most likely to benefit from
multimodality therapy, including conversion gastrectomy.
In the current study, the MST for stage IV gastric cancer
patients treated with multimodality therapy including DCS
followed by conversion gastrectomy was 29.9 months.
Among these patients, those with potentially resectable dis-
ease had a remarkably good prognosis and were selected as
the only significant prognostic factor.
Potentially resectable cases might be ideal candidates
for this curative strategy. However, the conclusions are
complicated by the fact that surgical cases are considered
to have relatively high chemosensitivity and good perfor-
mance status, leading to selection bias. The limitations of
our study also include its retrospective design in single
institute and small sample size. Because potentially resect-
able cases are very small population in gastric cancer,
further prospective multicenter trials with longer OS as
the primary endpoint are needed on the basis of our results
to allow the identification of patients who are likely to gain
a survival benefit from conversion surgery.
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